Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ligilactobacillus salivarius TCI153
- Development stage
- Unknown
- Lead developer
- TCI
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ligilactobacillus salivarius TCI153 is a probiotic strain developed by TCI Co., Ltd. for skin health and beauty applications. It operates through the gut-skin axis by modulating the gut microbiota and stimulating the endogenous production of sialic acid and epidermal growth factor (EGF). Clinical studies have demonstrated that oral supplementation with TCI153 significantly improves skin hydration, elasticity, and radiance while reducing melanin levels and transepidermal water loss (TEWL). The strain is typically formulated into "beauty-from-within" nutraceutical products, often in combination with vitamins and botanical extracts, and is commercially available in markets such as Taiwan.
- Other names
- Lactobacillus salivarius TCI153
02
Targets
SA (Sialic acid)
Beyond the preview
Go deeper on Ligilactobacillus salivarius TCI153.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ligilactobacillus salivarius TCI153.